Clozapine-induced severe mixed hyperlipidemia: a case report

General Hospital Psychiatry

Volumn 31, Issue 1, 2009, Pages 93-96

  Ahmed, Mohamed ^a   Griffin, Damian ^b   O'Toole, Ray ^b   McDonald, Colm ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Clozapine; Hypertriglyceridemia; Severe mixed hyperlipidemia

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; CLOZAPINE; FENOFIBRATE; METFORMIN; OLANZAPINE; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLOZAPINE INDUCED HYPERLIPIDEMIA; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; MALE; METABOLIC PARAMETERS; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

ANTIPSYCHOTIC AGENTS; CHOLESTEROL; CLOZAPINE; HUMANS; HYPERLIPIDEMIAS; IRELAND; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 58149136232     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2008.07.003     Document Type: Article

References (18)

1. De Hert M., Van Eyeck D., and De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21 (2006) 1-5
2. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (1998) 789-796
3. Allison D.B., Mentore J.M., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
4. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70 (2004) 1-17
5. Casey D.E. Dyslipidemia and atypical antipsychoic drugs. J Clin Psychiatry 65 (2004) 27-35
6. Henderson D.C., Daley T.B., Kunkel L., et al. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 65 (2004) 686-689
7. de Leon J., Susce M.T., Johnson M., et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 92 (2007) 95-102
8. Meyer J.M., Davis V.G., Goff D.C., McEvoy J.P., Nasrallah H.A., Davis S.M., Rosenheck R.A., Daumit G.L., Hsiao J., Swartz M.S., Stroup T.S., and Lieberman J.A. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101 (2008) 273-286
9. Baptista T., and Kin N.M.K.N.Y. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002) 205-219
10. Correll C. Balancing efficacy and safety in treatment with antipsychotics: an expert review of clinical challenges in psychiatry. CNS Spectr. 2007;12:10 (Suppl 17):12--20, 35.
11. Utermann G. Apolipoprotein E polymorphisms in health and disease. Am Heart J 113 (1987) 433-440
12. Arulmozhi D.K., Dwyer D.S., and Bodhankar S.L. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in miceLife. Sciences 79 19 (2006) 1865-1872
13. de Leon J., Correa J.C., Ruaño G., et al. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 98 1-3 (2008) 40-46
14. Meltzer H.Y., Burnett S., Bastani B., and Ramirez L.F. Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 41 (1990) 892-897
15. Cohn T.A., and Sernyak M.J. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 51 (2006) 492-501
16. De Hert M., van Eyck D., and De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21 (2006) S11-S16
17. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
18. Nasrallah H., McEvoy J., Meyer J., Goff D., and Davis S. Low rates of treatment for metabolic disorders in the CATIE schizophrenia trial at baseline: healthcare disparities in schizophrenia. Neuropsychopharmacology 30 (2005) S204